Huipeng Wan1, Linhong Zeng2, Ruihai Xiao3, Xiaoyi Tang4, Yan Shu5, Shaochen Shen6. 1. Medical College of Nanchang University, Nanchang, Jiangxi, China. 2. The First Affiliated Hospital of Nanchang University, Health Management Center, Nanchang, China. 3. Jiangxi Academy of Medical Sciences, Nanchang, China. 4. Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China. 5. The Second Hospital of Nanchang University, Health Management Center, No. 1 MinDe Road, 330006, Nanchang, China. 1150055027@qq.com. 6. The Second Hospital of Nanchang University, Health Management Center, No. 1 MinDe Road, 330006, Nanchang, China. 358155088@qq.com.
Abstract
INTRODUCTION: This meta-analysis aimed to identify the effect of colchicine on myocardial infarction (MI) in patients with gout. METHODS: In February 2021, a systematic computer-based search was conducted in PubMed, EMBASE, and Cochrane Database of Systematic Reviews. Data on patients with gout that compared colchicine versus others (no use of colchicine) were retrieved. The endpoints were the incidence rate for MI. After testing for heterogeneity between studies, data were aggregated for fixed-effects models when necessary. RESULTS: Three clinical studies with 3012 patients (colchicine group = 1523, control group = 1489) were finally included in the meta-analysis. Colchicine was associated with a decreased risk for myocardial infarction (pooled odds ratio 0.35, 95% confidence interval 0.23-0.55, p < 0.00001). CONCLUSIONS: Colchicine was effective in reducing the incidence of MI in patients with gout.
INTRODUCTION: This meta-analysis aimed to identify the effect of colchicine on myocardial infarction (MI) in patients with gout. METHODS: In February 2021, a systematic computer-based search was conducted in PubMed, EMBASE, and Cochrane Database of Systematic Reviews. Data on patients with gout that compared colchicine versus others (no use of colchicine) were retrieved. The endpoints were the incidence rate for MI. After testing for heterogeneity between studies, data were aggregated for fixed-effects models when necessary. RESULTS: Three clinical studies with 3012 patients (colchicine group = 1523, control group = 1489) were finally included in the meta-analysis. Colchicine was associated with a decreased risk for myocardial infarction (pooled odds ratio 0.35, 95% confidence interval 0.23-0.55, p < 0.00001). CONCLUSIONS: Colchicine was effective in reducing the incidence of MI in patients with gout.
Authors: MaryAnn Zhang; Daniel H Solomon; Rishi J Desai; Eun Ha Kang; Jun Liu; Tuhina Neogi; Seoyoung C Kim Journal: Circulation Date: 2018-09-11 Impact factor: 29.690